Is an Alzheimer’s Cure on the Horizon?

While Alzheimer’s is better understood today than in the past, no effective treatments for the disease have yet been found. One major challenge facing Alzheimer’s drug trials is finding participants. As GAP President John Dwyer says, “The biggest problem is that people are not aware of clinical trials. The fact is, the first person to […]

Read More…

When It Comes to Alzheimer’s, Important Changes Are Coming for MA Beneficiaries

In a joint op-ed with George Vradenburg, co-founder of UsAgainstAlzheimer’s, GAP President John Dwyer argues that the Centers for Medicare and Medicaid Services (CMS) has taken an important first step towards improving our health care system’s ability to address Alzheimer’s. By authorizing significant payments for Medicare Advantage beneficiaries with a diagnosis of dementia, CMS has […]

Read More…

In Year Three, GAP Trial Network Is Starting to Hum

This two-part feature covers the 2019 GAP-Net Site Optimization Conference and the many ways in which GAP is bringing its patient-centered, business-oriented approach to improve Alzheimer’s clinical trials. Representatives from several GAP-Net sites are quoted and mentioned in the piece, which details GAP’s effort to boost recruitment and unclog procedural bottlenecks, as well as its […]

Read More…

Addressing the GAPs in Alzheimer’s Trials, Treatment

In addition to covering the GAP-Net Site Optimization Conference, which took place in Nashville February 27 – March 1, the Nashville Medical News highlighted GAP’s efforts to speed and improve Alzheimer’s clinical trials through better administrative practices, a common IRB, and other disruptive tactics. The piece highlights two GAP-Net sites in Nashville: Clinical Research Associates and the Center for Cognitive […]

Read More…

A cure for Alzheimer’s is not possible without you

GAP President John Dwyer and Dr. Paul Newhouse, director of the GAP-Net site Center for Cognitive Medicine at Vanderbilt University Medical Center (VUMC), published an op-ed speaking to the importance of clinical trial participation in the fight to end Alzheimer’s. The piece, which highlights VUMC’s Alzheimer’s clinical trials, ran just before the 2nd annual GAP-Net Site Optimization […]

Read More…

Top Alzheimer’s Researchers Hope That Near-100 Dementia Drugs in Trials Are Moving Closer to a Breakthrough

Top Alzheimer’s Researchers Hope That Near-100 Dementia Drugs in Trials Are Moving Closer to a Breakthrough The search for a drug to treat Alzheimer’s disease, the most common form of dementia, has been marked by clinical trial failures. A new report from top researchers says the number of drugs advancing through clinical phase two and […]

Read More…